Health products policy and standards
Our team provides authoritative guidance and standards on quality, safety and efficacy of health products and supports countries to formulate evidence-based policies and ensure good practice throughout the value chain.
Expert Committees
Advisory groups
Databases
Publications
All →
5 September 2025
The selection and use of essential medicines, 2025: WHO AWaRe (Access, Watch, Reserve) classification...
he AWaRe classification is intended as a tool for monitoring antibiotic consumption, defining targets and monitoring the effects of stewardship policies...

5 September 2025
The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines for Children,...
Essential medicines are those that satisfy the priority health care needs of a population. They are selected with due regard to disease prevalence and...

5 September 2025
The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list
Essential medicines are those that satisfy the priority health care needs of a population. They are selected with due regard to disease prevalence and...

5 September 2025
The selection and use of essential medicines, 2025: report of the 25th WHO Expert Committee on Selection...
This executive summary reports the recommendations made by the Expert Committee on Selection and Use of Essential Medicines for the 2025 update of the...
Journal articles
Evolution of Ebola and Marburg Treatment Centers Design, a Review of the Last Ten Years of Outbreaks in Africa
Architecture 2024, 4(4), 930-947
Disease foci of pharmaceutical research and development as reflected in applications for International Nonproprietary Names, 1953–2022
Bulletin of the World Health Organization, Volume 103, Number 1, January 2025 1-80
WHO-listed authorities (WLA) framework: transparent evidence-based approach for promoting regulatory reliance towards increased access to quality-assured medical products
Frontiers in Medicine, 23 September 2024 Sec. Regulatory Science